| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 11. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | follitropin alfa (Ovaleap®) |
| Formulation | 300 IU/0.5 ml, 450 IU/0.75 ml and 900 IU/1.5 ml solution for injection |
| Reference number | 2255 |
| Indication | Anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate. Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies such as in vitro fertilisation, gamete intrafallopian transfer and zygote intrafallopian transfer. In association with a luteinising-hormone (LH) preparation for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials. these patients were defined by an endogenous serum LH level < 1.2 IU/l. Stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human-chorionic-gonadotropin therapy |
| Company | TEVA UK Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 06/12/2016 |